Targeted Therapeutics Under Investigation For PAH Treatment
In a world where vasodilators rule the landscape of treatments for pulmonary arterial hypertension (PAH), scientific research groups and pharmaceutical companies around the world are working to develop targeted therapeutics that focus on specific cellular pathways that are associated with dysfunction in PAH patients. Within the realm of targeted therapeutics, certain therapies are in basic research and others are at moderate-to-advanced stages of…
Research in the news: Scientists identify potential therapeutic target for pulmonary hypertension
Cardiovascular diseases are the leading cause of death worldwide. As a prime example, pulmonary hypertension is especially lethal, with one-half of patients dying within three years of being diagnosed. Yale researchers have uncovered a novel cell type that is essential to the development of pulmonary hypertension and promises to lead to improved therapies.
Pulmonary Hypertension Detection Aided By Non-invasive Doppler Echocardiography in New Study
Non-invasive techniques to detect pulmonary hypertension in individuals who are at a high risk for developing the disease are in high demand to enable more patients to be diagnosed and treated in the early stages. As the gold standard, right heart catheterization has been the primary mode of detecting an increase in pulmonary artery pressure, but other less invasive techniques such as transthoracic Doppler echocardiography may be useful to detect…
Pulmonary hypertension: A growing problem in US children
Fast Facts: Study reveals pediatric pulmonary hypertension hospitalizations on the rise, resulting in skyrocketing costs. Findings uncover need to initiate a national registry to track individual patients over time and to provide a foundation for clinical trials to test new and better treatments. Study finds pulmonary hypertension hospitalizations now higher in children without congenital heart disease. A review of 15 years' worth of data in a …
Researchers Publish The Most Comprehensive Data Ever on PAH Genes
An international group of scientists has comprehensively characterized the genetics of pulmonary arterial hypertension (PAH). This new information could ultimately help clinicians treat the disease based on individual traits and genetic makeup. This is the most complete set of genetic data that has been collected about the disease to date.
Bellerophon phase II win could mean new portable option in PAH
Bellerophon Therapeutics Inc.'s inhaled nitric oxide seems poised to become a key add-on, orphan therapy in pulmonary arterial hypertension (PAH) and, if all goes well, could also end up the only approved therapy in pulmonary hypertension when associated with chronic obstructive pulmonary disease (COPD).
Meta-analysis: Exercise training benefits patients with pulmonary hypertension
Exercise training is safe and effective for patients with pulmonary hypertension, according to a meta-analysis published in Circulation: Heart Failure.
Calcilytics Could be Used to Treat Idiopathic Pulmonary Arterial Hypertension
A recent study from Japan has shown that dividing cells involved in causing idiopathic pulmonary arterial hypertension (IPAH) may be stopped with a new type of drug called a calcilytic. The research could led to new treatments for IPAH. The study, titled “Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension“ appeared September 16, 2015 in the online journal PLoS One.
Individual treatment a must for PAH patients
A Cornwall resident and ambassador for the Pulmonary Hypertension Association of Canada will be advocating against a one-size-fits-all approach toward the rare, life-threatening lung disease.
Low-Intensity Exercise Appears Safe for Pulmonary Hypertension
Exercise has a positive effect on several measures of heart function as well as overall quality of life for patients with pulmonary hypertension, according to research published recently in Circulation: Heart Failure.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter